Clinical trials: Allogeneic Disease
Heart Failure
Treating Heart Failure With hPSC-CMs
Heart failure has a high morbidity and mortality because the heart is one of the least regenerative organs in the human body. Drug treatments for heart failure manage symptoms but do not restore lost myocytes.
- Trial name
- HEAL-CHF (NCT03763136)
- Testing
- hPSC-CM Therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- HELP Therapeutics Co., Ltd.
Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma
Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
This example phase 1/2, open-label, biomarker-selected study evaluates EB-HC01, an allogeneic dual-target CARNK product composed of a 1:1 mixture of HER2-CAR-NK and CEACAM5-CAR-NK cells, in adults with unresectable or metastatic…
- Conditions
- Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma
- Trial name
- DUET-BTC (NCT07641036)
- Testing
- EB-HC01 dual-target CARNK cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Biotech
Acute Myeloid Leukemias, Advanced Hematological Malignancies
Haploidentical Transplantation With Early Adoptive Transfer of CD56+CD3- NK Cells
Experimental and clinical data suggest that alloreactive NK cells can reduce the risk of graft-rejection, GvHD and leukemic relapse after HLA-mismatched transplantation.
- Conditions
- Acute Myeloid Leukemias, Advanced Hematological Malignancies, Indication for Allogeneic Stem Cell Transplantation, no HLA-identical Donor Available
- Trial name
- NCT01220544
- Testing
- Haploidentical transplantation with donor NK cells
- Where
- 2 sites in Germany
- Volunteers
- 30 people
- Sponsor
- Charite University, Berlin, Germany
Leukemia, B-cell
γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse
Safety and Effectiveness of Donor γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
- Trial name
- γδT (NCT04439721)
- Testing
- γδT Cell infusion agent
- Where
- China
- Volunteers
- 5 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Blood Cancer, Multiple Myeloma
Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma
Mixed chimerism transplantation is an approach to allogeneic transplants that attempts to decrease regimen-related toxicity by using non-myeloablative preparatory regimens; establish mixed chimerism using low dose total body…
- Trial name
- NCT00185614
- Testing
- Autologous hematopoietic cell transplant (Auto-HCT), Allogeneic hematopoietic cell transplant (Allo-HCT), Cyclophosphamide
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Wen-Kai Weng
Hematological Malignancies
An Evaluation of the Effect of 'Open Window' on Psychological Well-being and Experience of Stem Cell Transplantation
The 'Open Window' Study is a prospective longitudinal study using a 4 group randomised control trial design to evaluate the psychological effect of 'Open Window' on the consequences of long term isolation on patients undergoing…
- Trial name
- NCT00348959
- Testing
- 'Open Window' Project
- Where
- Ireland
- Volunteers
- 198 people
- Sponsor
- St. James's Hospital, Ireland
Hematologic Malignancies
Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation
In this trial, we aim to improve the outcomes of haplo cord transplant. Haplo cord transplant is a novel and promising way to improve transplant outcomes.
- Trial name
- NCT01810588
- Testing
- CliniMACS® CD34 Reagent System, Fludarabine, Melphalan
- Where
- 2 sites in United States
- Volunteers
- 270 people
- Sponsor
- Weill Medical College of Cornell University
Multiple Myeloma
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
Multiple myeloma (MM) is the second most common hematologic malignancy in adults. The current standard of care for MM patients fit to undergo high dose conditioning chemotherapy is an autologous HCT (autoHCT).
- Trial name
- NCT03127761
- Testing
- Allogeneic Hematopoietic Stem Cell Transplant
- Where
- United States
- Volunteers
- 544 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Graft Versus Host Disease, Hematologic Malignancies
Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation
The main purpose of this study is to evaluate the effect of palifermin versus placebo in the reduction of severe acute graft versus host disease (GVHD) and severe oral mucositis.
- Trial name
- NCT00189488
- Testing
- Palifermin, Conditioning Regimen, Allogeneic stem cell transplant
- Volunteers
- 155 people
- Sponsor
- Swedish Orphan Biovitrum
Myocardial Infarction
Ex Vivo Cultured Bone Marrow Derived Allogenic MSCs in AMI
This clinical trial aims to find out the safety and efficacy of adult mesenchymal stem cells in patients with myocardial infarction.
- Trial name
- NCT00883727
- Testing
- Stem cell, Plasmalyte A
- Where
- 4 sites in India
- Volunteers
- 20 people
- Sponsor
- Stempeutics Research Pvt Ltd
Aplastic Anemia
CD7 CAR-T Bridging to alloHSCT for Severe Aplastic Anemia
This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 CAR-T Bridging to allo-HSCT therapy for patients with severe aplastic anemia
- Trial name
- NCT06633328
- Testing
- CD7 CAR-T cells injection, Allogeneic hematopoietic stem cell transplantation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang University
Chronic Myeloproliferative Disorders, Leukemia
Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004181
- Testing
- busulfan, cyclophosphamide, allogeneic bone marrow transplantation
- Where
- United States
- Sponsor
- Northwestern University
COVID - 19
A Phase II Safety and Tolerability Study of TCB008 in Patients With COVID-19
A Phase II safety and tolerability study of expanded gamma delta T cell lymphocytes (TCB008) in patients diagnosed with COVID-19.
- Trial name
- NCT04834128
- Testing
- TCB008
- Where
- United Kingdom
- Sponsor
- TC Biopharm
Brain Injury, Cerebral Palsy
Combination Therapy of Cord Blood and G-CSF for Patients With Brain Injury or Neurodegenerative Disorders
This open label trial is conducted to investigate the efficacy and safety of the combination therapy of allogeneic umbilical cord blood (UCB) and granulocyte-colony stimulating factor (G-CSF) for patients with brain injury or…
- Conditions
- Brain Injury, Cerebral Palsy, Amyotrophic Lateral Sclerosis, Parkinson's Disease
- Trial name
- NCT02236065
- Testing
- Umbilical cord blood therapy, Filgrastim
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- MinYoung Kim, M.D.
Multiple Myeloma
FM 140 vs FM100 Study in Patients With Multiple Myeloma
The goal of this clinical research study is to learn if there is a difference in transplant outcomes between two different doses of melphalan given in combination with fludarabine followed by transfusion of a related or unrelated…
- Trial name
- NCT00505895
- Testing
- Melphalan, Fludarabine, Stem Cell Infusion
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- M.D. Anderson Cancer Center
Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Stem Cell Transplantation
TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
The purpose of this study is to evaluate the efficacy of tyrosine kinase inhibitor(TKI) therapy based on molecular monitoring of BCR/ABL levels in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)undergoing…
- Conditions
- Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Stem Cell Transplantation, Minimal Residual Disease
- Trial name
- NCT01883219
- Testing
- TKIs
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Nanfang Hospital, Southern Medical University
B-Cell Non-Hodgkin Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm
Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies
This pilot clinical trial studies the side effects of lenalidomide and ipilimumab after stem cell transplant in treating patients with hematologic or lymphoid malignancies.
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Leukemia, Lymphoma
- Trial name
- NCT01919619
- Testing
- Ipilimumab, Lenalidomide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions
The patients are being offered a stem cell transplant. Stem cells are very early blood cells. They have not yet matured to become red or white blood cells or platelets.
- Trial name
- NCT01131169
- Testing
- busulfan, melphalan and fludarabine
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Abdominal Aortic Aneurysm
Safety and Efficacy of Allogeneic MSCs in Promoting T-regulatory Cells in Patients With Small Abdominal Aortic Aneurysms
This project is to determine the safety and explore the effectiveness of allogeneic (not cells of the participant but those of another human) mesenchymal stromal cells (MSCs) in decreasing inflammation and possible enlargement of…
- Trial name
- VIVAAA (NCT02846883)
- Testing
- 1 million MSCs/kg, 3 million MSCs/kg
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- VA Office of Research and Development
Melanoma
Vaccination of Melanoma Patients With Dendritic Cells Loaded With Allogeneic Apoptotic-Necrotic Melanoma Cells
Background: Sixteen melanoma patients (1 stage IIC, 8 stage III, and 7 stage IV) were treated in a Phase I study to evaluate safety and immune responses, with a vaccine (DC/Apo-Nec) composed of autologous dendritic cells (DCs)…
- Trial name
- NCT00515983
- Testing
- DC/Apo-Nec
- Where
- Argentina
- Volunteers
- 16 people
- Sponsor
- José Mordoh, M.D., Ph.D.